Earnings History Data for Arcutis Biotherapeutics (ARQT) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 06-11-2024 | AH | ARQT | Arcutis Biotherapeutics | 1,019 | -0.33 | -0.42 | 0.00 | Arcutis Biotherapeutics GAAP EPS of -$0.33 beats by $0.09, revenue of $44.75M beats by $7.41M [11/6/2024 4:02 PM] |
10.41 | 0.75 (7.82%) |
10.13 | 0.47 (4.87%) |
1.76 - 13.17 | 4,264,673 | 1,990,000 | 14,937 | ||
| 14-08-2024 | AH | ARQT | Arcutis Biotherapeutics, Inc. | 1,120 | -0.42 | -0.48 | -1.16 | Arcutis Biotherapeutics GAAP EPS of -$0.42 beats by $0.09, revenue of $30.85M beats by $1.77M [8/14/2024 4:16 PM] |
8.51 | -1.07 (-11.22%) |
9.16 | -0.42 (-4.38%) |
1.76 - 13.17 | 6,381,812 | 2,110,000 | 51,866 | ||
| 14-05-2024 | AH | ARQT | Arcutis Biotherapeutics, Inc. | 759.02 | -0.32 | -0.60 | -1.31 | Arcutis Biotherapeutics GAAP EPS of -$0.32 beats by $0.41, revenue of $49.56M [5/14/2024 4:22 PM] |
9.15 | 1.02 (12.55%) |
9.38 | 1.25 (15.38%) |
1.76 - 13.17 | 11,998,331 | 2,690,000 | 1,041,791 | ||
| 27-02-2024 | PM | ARQT | Arcutis Biotherapeutics, Inc. | 913.62 | -0.72 | -0.64 | -1.18 | Arcutis Biotherapeutics GAAP EPS of -$0.72, revenue of $13.5M [2/27/2024 5:52 AM] |
10.70 | 1.01 (10.37%) |
10.59 | 0.90 (9.29%) |
1.76 - 17.57 | 8,527,009 | 4,930,000 | 189,394 | ||
| 03-11-2023 | PM | ARQT | Arcutis Biotherapeutics, Inc. | 138.72 | -0.73 | -0.90 | -1.89 | Arcutis Biotherapeutics GAAP EPS of -$0.73 beats by $0.15, revenue of $38.1M beats by $7.28M [11/3/2023 7:43 AM] |
2.44 | 0.22 (9.91%) |
2.48 | 0.26 (11.71%) |
2.13 - 20.11 | 3,272,826 | 5,500,000 | 11,063 | ||
| 08-08-2023 | AH | ARQT | Arcutis Biotherapeutics, Inc. | 603.78 | -1.16 | -1.22 | -1.31 | Arcutis Biotherapeutics GAAP EPS of -$1.16 beats by $0.08, revenue of $5.2M beats by $0.58M [8/8/2023 4:15 PM] |
9.37 | -0.46 (-4.68%) |
10.15 | 0.32 (3.26%) |
7.25 - 27.40 | 787,400 | 720,000 | 217 | ||
| 09-05-2023 | AH | 4:00 PM ET (May 9) |
ARQT | Arcutis Biotherapeutics, Inc. | 893.42 | -1.31 | -1.29 | -1.27 | Arcutis Biotherapeutics reports Q1 results [5/9/2023 5:09 PM] |
12.04 | -2.79 (-18.79%) |
14.82 | 0.0 (0.00%) |
10.05 - 27.40 | 3,927,306 | 760,000 | 26,179 | |
| 28-02-2023 | AH | 4:00 PM ET (Feb 28) |
ARQT | Arcutis Biotherapeutics, Inc. | 966.92 | -1.18 | -1.37 | -1.42 | Arcutis Biotherapeutics Q4 results beat estimates [2/28/2023 5:10 PM] |
16.70 | 0.52 (3.21%) |
16.18 | 0.0 (0.00%) |
12.81 - 27.40 | 969,316 | 720,000 | 102,921 | |
| 08-11-2022 | AH | 4:00 PM ET (Nov 8) |
ARQT | Arcutis Biotherapeutics, Inc. | 1,080 | -1.89 | -1.54 | -1.14 | Arcutis Biotherapeutics GAAP EPS of -$1.89 misses by $0.01, revenue of $0.73M beats by $0.07M [11/8/2022 4:05 PM] |
18.62 | -0.08 (-0.43%) |
18.70 | 0.0 (0.00%) |
13.59 - 27.40 | 839,860 | 610,000 | 9,421 | |
| 05-05-2022 | AH | ARQT | Arcutis Biotherapeutics | 1,106 | -1.27 | -1.42 | 0.00 | Arcutis Biotherapeutics GAAP EPS of -$1.27 beats by $0.22 [5/5/2022 5:48 PM] |
19.52 | -1.50 (-7.14%) |
21.02 | 0.0 (0.00%) |
13.59 - 35.21 | 320,612 | 230,000 | 904 | ||
| 05-08-2021 | AH | 4:50 PM ET (Aug 5) |
ARQT | Arcutis Biotherapeutics, Inc. | 1,147 | -0.84 | -0.91 | 0.00 | Arcutis Biotherapeutics EPS beats by $0.13 [8/5/2021 5:28 PM] |
21.42 | -0.41 (-1.88%) |
22.00 | 0.17 (0.78%) |
17.51 - 38.49 | 83,954 | 170,000 | 1,565 | |
| 16-02-2021 | AH | ARQT | Arcutis Biotherapeutics, Inc. | 1,531 | -0.79 | -0.89 | 0.00 | Arcutis Biotherapeutics EPS beats by $0.06 [2/16/2021 5:00 PM] |
35.27 | 1.58 (4.69%) |
33.69 | 0.0 (0.00%) |
17.10 - 40.88 | 451,634 | 488,797 | 144 | ||
| 11-08-2020 | AH | ARQT | Arcutis Biotherapeutics, Inc. | 924.10 | -0.94 | 0.00 | 0.00 | Arcutis Biotherapeutics EPS misses by $0.11 [8/11/2020 4:29 PM] |
25.02 | 0.36 (1.46%) |
24.66 | 0.0 (0.00%) |
17.10 - 40.88 | 62,408 | 102,073 | 127 | ||
|
|
||||||||||||||||||